Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine - PubMed
Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine
S B Murphy et al. J Clin Oncol. 1986 Dec.
Abstract
To address the problem of historically poor results in the treatment of children with advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia (ALL), an intensive chemotherapy regimen was devised using the most effective single agents in high-dose short courses. Treatment commenced with a fractionated schedule of intravenous (IV) cyclophosphamide (300 mg/m2 every 12 hours for six doses) followed immediately by Adriamycin (50 mg/m2) and vincristine (1.5 mg/m2) with combined intrathecal (IT) methotrexate and cytarabine. Predictably, this treatment produced virtually complete disappearance of all tumor and profound myelosuppression. Immediately on hematologic recovery, IV high-dose methotrexate (1,000 mg/m2 over 24 hours) followed by IV cytarabine (400 mg/m2 over the next 48 hours) was administered with leucovorin rescue and repeated IT treatments. The treatment sequence described above is repeated four times, with the dose of cytarabine doubled in succeeding courses, up to 3,200 mg/m2. The entire planned therapy required approximately 24 weeks. Since 1981, we treated a total of 29 children with this approach, 19 of whom had massive unresectable intraabdominal tumor. According to initial extent of disease, 17 were classified as stage III, four as stage IV non-Hodgkin's lymphoma (NHL), and eight as B cell ALL. Eight of the 12 patients with stage IV NHL or B cell ALL had initial involvement of the CNS. Twenty-seven of 29 patients (93%) attained a complete remission. Fourteen of 17 stage III NHL patients remain disease free, for periods ranging from 3+ months to 4 1/2+ years. The actuarial estimate of the proportion of stage III patients remaining disease free at 2 years is 81%. Results in patients with initial involvement of the CNS and/or marrow are much less favorable, with only two of ten patients who attained remission apparently being cured. In addition to stage, the initial serum lactic dehydrogenase (LDH) level emerged as a prognostic indicator, higher levels (over 1,000 IU/L) being associated with the worst prognosis (P less than .05). Major toxicity consisted of severe hematopoietic suppression and febrile episodes associated with neutropenia. We conclude that this treatment is highly effective for advanced-stage Burkitt's tumors in children free of initial CNS involvement.
Similar articles
-
Schwenn MR, Blattner SR, Lynch E, Weinstein HJ. Schwenn MR, et al. J Clin Oncol. 1991 Jan;9(1):133-8. doi: 10.1200/JCO.1991.9.1.133. J Clin Oncol. 1991. PMID: 1985162 Clinical Trial.
-
Sun XF, Zhen ZJ, Liu DG, Xia Y, Xiang XJ, Chen XQ, Ling JY, Zheng L, Luo WB, Lin H, He YJ, Guan ZZ. Sun XF, et al. Ai Zheng. 2007 Dec;26(12):1339-43. Ai Zheng. 2007. PMID: 18076797 Chinese.
-
Therapy of B-cell acute lymphoblastic leukaemia in childhood: the BFM experience.
Reiter A. Reiter A. Baillieres Clin Haematol. 1994 Jun;7(2):321-37. doi: 10.1016/s0950-3536(05)80205-7. Baillieres Clin Haematol. 1994. PMID: 7803904 Review.
-
Hagemeister FB. Hagemeister FB. Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
Cited by
-
Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H. Thomas D, et al. Cancer. 2010 Oct 1;116(19):4580-9. doi: 10.1002/cncr.25319. Cancer. 2010. PMID: 20572037 Free PMC article.
-
Acute lymphoblastic leukemia: optimizing treatment strategies in children.
Vora A. Vora A. Paediatr Drugs. 2002;4(6):405-16. doi: 10.2165/00128072-200204060-00007. Paediatr Drugs. 2002. PMID: 12038876 Review.
-
Sayed-Ahmed MM. Sayed-Ahmed MM. Clin Exp Nephrol. 2010 Oct;14(5):418-26. doi: 10.1007/s10157-010-0321-0. Epub 2010 Jul 23. Clin Exp Nephrol. 2010. PMID: 20652348
-
Rizzieri DA, Johnson JL, Byrd JC, Lozanski G, Blum KA, Powell BL, Shea TC, Nattam S, Hoke E, Cheson BD, Larson RA; Alliance for Clinical Trials In Oncology (ACTION). Rizzieri DA, et al. Br J Haematol. 2014 Apr;165(1):102-11. doi: 10.1111/bjh.12736. Epub 2014 Jan 15. Br J Haematol. 2014. PMID: 24428673 Free PMC article.
-
Thomas DA, O'Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, Wierda W, Ravandi F, Verstovsek S, Jorgensen JL, Bueso-Ramos C, Andreeff M, Pierce S, Garris R, Keating MJ, Cortes J, Kantarjian HM. Thomas DA, et al. J Clin Oncol. 2010 Aug 20;28(24):3880-9. doi: 10.1200/JCO.2009.26.9456. Epub 2010 Jul 26. J Clin Oncol. 2010. PMID: 20660823 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical